Tandem Diabetes Care Inc at UBS Genomics 2.0 and MedTech Innovations Summit Transcript

Aug 16, 2023 / 06:00PM GMT
Danielle Joy Antalffy - UBS Investment Bank, Research Division - Analyst

Good morning, everyone. Thank you for joining us for the last session of the morning. I am Danielle Antalffy. I'm the medtech analyst in the U.S. here at UBS and very excited to have with us the company I've known for a very long time, Tandem Diabetes. CEO, John Sheridan; CFO, Leigh Vosseller. Thank you guys for joining us. I know you drove very far to get here.

John F. Sheridan - Tandem Diabetes Care, Inc. - President, CEO & Director

Thanks for having us.

Questions and Answers:

Danielle Joy Antalffy - UBS Investment Bank, Research Division - Analyst

You are welcome. So one of the questions I want to ask you guys after several years of a very strong stock performance. It's been a tough few quarters here. And I just wanted to maybe start with a question I actually usually end with. And that is, what do you think investor sell-side might be missing about the Tandem story that has been driving some of the stock underperformance recently.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot